Sino Medical Sciences Technology, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003NY2
  • SHG: 688108
CNY
16.08
0.14 (0.88%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

The company is Net-Debt Free

  • Poor long term growth as Net Sales has grown by an annual rate of 14.80% and Operating profit at 29.84% over the last 5 years
  • The company is Net-Debt Free
2

Poor long term growth as Net Sales has grown by an annual rate of 14.80% and Operating profit at 29.84% over the last 5 years

 
3

With a growth in Net Sales of 18.01%, the company declared Very Positive results in Jun 26

4

With ROE of 7.24%, it has a expensive valuation with a 7.65 Price to Book Value

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 5,521 Million (Mid Cap)

stock-summary
P/E

106.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.25

stock-summary
Return on Equity

7.24%

stock-summary
Price to Book

5.57

Revenue and Profits:
Net Sales:
165 Million
(Quarterly Results - Jun 2026)
Net Profit:
28 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.37%
0%
-17.37%
6 Months
-20.87%
0%
-20.87%
1 Year
-43.99%
0%
-43.99%
2 Years
82.73%
0%
82.73%
3 Years
52.42%
0%
52.42%
4 Years
198.88%
0%
198.88%
5 Years
82.52%
0%
82.52%

Sino Medical Sciences Technology, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
14.80%
EBIT Growth (5y)
29.84%
EBIT to Interest (avg)
-48.82
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.43
Tax Ratio
23.98%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.08%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
106
Industry P/E
Price to Book Value
7.65
EV to EBIT
94.93
EV to EBITDA
50.23
EV to Capital Employed
9.88
EV to Sales
13.01
PEG Ratio
0.09
Dividend Yield
NA
ROCE (Latest)
10.41%
ROE (Latest)
7.24%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 18.04% vs -13.55% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 5.17% vs 1.50% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "164.90",
          "val2": "139.70",
          "chgp": "18.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "55.60",
          "val2": "47.20",
          "chgp": "17.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "28.50",
          "val2": "27.10",
          "chgp": "5.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "225.30%",
          "val2": "205.70%",
          "chgp": "1.96%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 14.15% vs 33.30% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1,317.95% vs 91.01% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "519.50",
          "val2": "455.10",
          "chgp": "14.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "141.60",
          "val2": "57.40",
          "chgp": "146.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.30",
          "val2": "5.80",
          "chgp": "-8.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "47.50",
          "val2": "-3.90",
          "chgp": "1,317.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "92.10%",
          "val2": "-99.20%",
          "chgp": "19.13%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
164.90
139.70
18.04%
Operating Profit (PBDIT) excl Other Income
55.60
47.20
17.80%
Interest
1.00
1.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
28.50
27.10
5.17%
Operating Profit Margin (Excl OI)
225.30%
205.70%
1.96%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is 18.04% vs -13.55% in Mar 2026

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 5.17% vs 1.50% in Mar 2026

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
519.50
455.10
14.15%
Operating Profit (PBDIT) excl Other Income
141.60
57.40
146.69%
Interest
5.30
5.80
-8.62%
Exceptional Items
0.20
0.00
Consolidate Net Profit
47.50
-3.90
1,317.95%
Operating Profit Margin (Excl OI)
92.10%
-99.20%
19.13%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 14.15% vs 33.30% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 1,317.95% vs 91.01% in Dec 2024

stock-summaryCompany CV
About Sino Medical Sciences Technology, Inc. stock-summary
stock-summary
Sino Medical Sciences Technology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available